Cassava Sciences Inc. has surged by 925% to claim the top biotech spot this year as investors weighed its possible treatment for Alzheimer’s disease, Bloomberg reported.

Cassava Sciences Inc chart
  • Cassava jumped as much as 8.4% to hit $73.26 apiece in New York on Tuesday morning, levels not seen in the past 20 years.
  • Cassava jumped as much as 8.4% to hit $73.26 apiece in New York on Tuesday morning, levels not seen in the past 20 years.
  • Cassava jumped as much as 8.4% to hit $73.26 apiece in New York on Tuesday morning, levels not seen in the past 20 years.
  • Cassava jumped as much as 8.4% to hit $73.26 apiece in New York on Tuesday morning, levels not seen in the past 20 years.

Analysts have set a price target of $110 for Cassava. SAVA is down 0.92%, while BIIB is down 5.33%.